Frank DAmelio - Pfizer President
PFE Stock | USD 28.82 0.44 1.55% |
President
Mr. Frank A. DAmelio is the Chief Financial Officer, Executive Vice President Business Operations of the Company. He was Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Prior to joining Pfizer, he was Senior Executive Vice President of Integration and Chief Administrative Officer of AlcatelLucent from November 2006 until August 2007. Prior to the AlcatelLucent merger, he was Chief Operating Officer of Lucent and before that Chief Financial Officer of Lucent. Director of Zoetis Inc. and of Humana Inc. and Chair of the Humana Audit Committee. He is a Director of the Independent College Fund of New Jersey. since 2022.
Age | 66 |
Tenure | 2 years |
Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
As of May 16, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 10 records | PRESIDENT Age | ||
Donghee Suh | LG Display Co | N/A | |
Corey Ruehle | United Fire Group | 50 | |
Tae Kim | LG Display Co | 55 | |
Dong Suh | LG Display Co | N/A | |
Yu In | LG Display Co | 62 | |
Michael Sheeley | United Fire Group | 63 | |
Hyeong Choi | LG Display Co | 58 | |
Jeong Shin | LG Display Co | 57 | |
Robert Cataldo | United Fire Group | 53 | |
MyoungKyu Kim | LG Display Co | 61 |
Management Performance
Return On Equity | -0.0026 | ||||
Return On Asset | 0.0093 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
Shantanu Narayen, Lead Independent Director | ||
James Smith, Independent Director | ||
Christopher CFA, VP Officer | ||
Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
Susan DesmondHellmann, Independent Director | ||
Francesca DeMartino, Chief Officer | ||
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
Gordon Loh, Senior Vice President Corporate Audit | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
DVM DVM, Chairman CEO | ||
William Gray, Independent Director | ||
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
Susan Hockfield, Independent Director | ||
William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
Mikael MD, Chief Development | ||
Albert DVM, Chairman CEO | ||
Dan Littman, Independent Director | ||
Payal Becher, Chief VP | ||
James Kilts, Independent Director | ||
James Quincey, Independent Director | ||
Andreas Panayiotou, Global Officer | ||
Joseph Echevarria, Independent Director | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Scott Gottlieb, Independent Director | ||
Ronald Blaylock, Independent Director |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0026 | ||||
Return On Asset | 0.0093 | ||||
Profit Margin | (0.01) % | ||||
Operating Margin | 0.32 % | ||||
Current Valuation | 219.07 B | ||||
Shares Outstanding | 5.67 B | ||||
Shares Owned By Insiders | 0.04 % | ||||
Shares Owned By Institutions | 69.06 % | ||||
Number Of Shares Shorted | 62.51 M | ||||
Price To Earning | 9.48 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Dividend Share 1.65 | Earnings Share (0.05) | Revenue Per Share 9.717 | Quarterly Revenue Growth (0.20) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.